# US 2013/0210761 A1 · Methods and compositions for treating wounds utilizing chitosan compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0210761 A1
- Document ID: US20130210761A1
- Status: Published application
- Kind: A1
- Application number: 13/639,560
- Filed: 2011-04-06
- Published: 2013-08-15
- Earliest claimed: 2010-04-06
- Assignees: Synedgen, Inc.
- Inventors: Shenda Baker; William P. Wiesmann; Ruth Baxter
- Web page: https://patentgrep.com/patent/US20130210761A1

## CPC

- A61K 31/722: Chitin, chitosan
- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61L 26/0023: {Polysaccharides}
- A61L 26/0066: {Medicaments; Biocides}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 13/12: of the kidneys
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C08L 5/08: Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
- A61L 2300/404: Biocides, antimicrobial agents, antiseptic agents
- A61L 2300/41: Anti-inflammatory agents, e.g. NSAIDs
- A61L 2300/64: Animal cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)

## Abstract

Described herein are methods of treating wounds, the method comprising administering to a subject an effective amount of a composition comprising a soluble or derivatized chitosan wherein the soluble or derivatized chitosan when administered contacts the wound, thereby treating the wound.

## Claims

### Claim at position 1

1-65. (canceled)

### Claim 66

A method of treating mucositis or ulceration, or a symptom of mucositis or ulceration, the method comprising administering to a subject an effective amount of a composition comprising a soluble or derivatized chitosan, wherein the derivatized chitosan comprises a chitosan of the following formula (I):
wherein:
n is an integer between 20 and 6000; and
each R1 is independently selected for each occurrence from hydrogen, acetyl, and a group of formula (II):
wherein at least 25% of R1 substituents are H, at least 1% of R1 substituents are acetyl, and 4-30% of R1 substituents are a group of formula (II),
thereby treating mucositis or ulceration, or the symptom of mucositis or ulceration.

### Claim 67

A method of treating a symptom of a chronic disease, the method comprising administering to a subject an effective amount of a composition comprising a soluble or derivatized chitosan, wherein the derivatized chitosan comprises a chitosan of the following formula (I):
wherein:
n is an integer between 20 and 6000; and
each R1 is independently selected for each occurrence from hydrogen, acetyl, and a group of formula (II):
wherein at least 25% of R1 substituents are H, at least 1% of R1 substituents are acetyl, and 4-30% of R1 substituents are a group of formula (II),
thereby treating the symptom of the chronic disease.

### Claim 68

A method of treating a wound in a subject, wherein the wound is a result of an acute or chronic infection, or the wound is not infected, the method comprising administering to a subject an effective amount of a composition comprising a soluble or derivatized chitosan, wherein the derivatized chitosan comprises a chitosan of the following formula (I):
wherein:
n is an integer between 20 and 6000; and
each R1 is independently selected for each occurrence from hydrogen, acetyl, and a group of formula (II):
wherein at least 25% of R1 substituents are H, at least 1% of R1 substituents are acetyl, and 4-30% of R1 substituents are a group of formula (II),
thereby treating the wound.

### Claim 69

(canceled)

### Claim 70

A method of treating a subject who has been treated or is being treated for cancer with a cancer therapy, the method comprising administering to the subject an effective amount of a composition comprising a soluble or derivatized chitosan, wherein the derivatized chitosan comprises a chitosan of the following formula (I):
wherein:
n is an integer between 20 and 6000; and
each R1 is independently selected for each occurrence from hydrogen, acetyl, and a group of formula (II):
wherein at least 25% of R1 substituents are H, at least 1% of R1 substituents are acetyl, and 4-30% of R1 substituents are a group of formula (II),
thereby treating the subject.

### Claim at position 7

71-73. (canceled)

### Claim 74

A method of treating a subject receiving a surgical procedure or having undergone a surgical procedure, the method comprising administering to a subject an effective amount of a composition comprising a soluble or derivatized chitosan, wherein the derivatized chitosan comprises a chitosan of the following formula (I):
wherein:
n is an integer between 20 and 6000; and
each R1 is independently selected for each occurrence from hydrogen, acetyl, and a group of formula (II):
wherein at least 25% of R1 substituents are H, at least 1% of R1 substituents are acetyl, and 4-30% of R1 substituents are a group of formula (II),
thereby treating the subject.

### Claim at position 9

75-79. (canceled)

### Claim 80 (depends on 66)

The method of claim 66, wherein the composition, upon administration, reduces the healing time or increases the healing rate of the mucositis or ulceration.

### Claim 81 (depends on 66)

The method of claim 66, wherein the mucositis or ulceration is associated with inflammation and the composition decreases the inflammation upon administration.

### Claim 82 (depends on 66)

The method of claim 66, wherein the composition is administered topically or orally.

### Claim 83 (depends on 66)

The method of claim 66, wherein the molecular weight of the functionalized chitosan is between 5,000 and 1,000,000 Da.

### Claim 84 (depends on 67)

The method of claim 67, wherein the composition, upon administration, reduces the healing time or increases the healing rate of the symptom of the chronic disease.

### Claim 85 (depends on 67)

The method of claim 67, wherein the symptom of the chronic disease is associated with inflammation and the composition decreases the inflammation upon administration.

### Claim 86 (depends on 67)

The method of claim 67, wherein the composition is administered topically or orally.

### Claim 87 (depends on 67)

The method of claim 67, wherein the molecular weight of the functionalized chitosan is between 5,000 and 1,000,000 Da.

### Claim 88 (depends on 68)

The method of claim 68, wherein the composition, upon administration, reduces the healing time or increases the healing rate of the wound.

### Claim 89 (depends on 68)

The method of claim 68, wherein the composition, upon administration, decreases the inflammation associated with wound or healing of the wound.

### Claim 90 (depends on 68)

The method of claim 68, wherein the composition is administered topically or orally.

### Claim 91 (depends on 68)

The method of claim 68, wherein the molecular weight of the functionalized chitosan is between 5,000 and 1,000,000 Da.

### Claim 92 (depends on 70)

The method of claim 70, wherein the cancer therapy is associated with a side effect and the composition decreases the side effect upon administration.

### Claim 93 (depends on 70)

The method of claim 70, wherein the cancer therapy is chemotherapy or radiation therapy.

### Claim 94 (depends on 70)

The method of claim 70, wherein the composition is administered topically or orally.

### Claim 95 (depends on 70)

The method of claim 70, wherein the molecular weight of the functionalized chitosan is between 5,000 and 1,000,000 Da.

### Claim 96 (depends on 74)

The method of claim 74, wherein the surgical procedure results in a wound, and the composition, upon administration, reduces the healing time or increases the healing rate of the wound.

### Claim 97 (depends on 96)

The method of claim 96, wherein the composition, upon administration, decreases the inflammation associated with the wound or healing of the wound.

### Claim 98 (depends on 74)

The method of claim 74, wherein the composition is administered topically or orally.

### Claim 99 (depends on 74)

The method of claim 74, wherein the molecular weight of the functionalized chitosan is between 5,000 and 1,000,000 Da.
